How to buy Neos Therapeutics stock

Neos Therapeutics, Inc is a drug manufacturers-specialty & generic business based in the US. Neos Therapeutics shares (NEOS) are listed on the NASDAQ and all prices are listed in US Dollars. Neos Therapeutics employs 213 staff and has a trailing 12-month revenue of around 0.00.

Neos Therapeutics share price

Use our graph to track the performance of NEOS stocks over time.

Neos Therapeutics shares at a glance

• Key figures

Information last updated 2021-03-10.

52-week range	$0.45 - $1.37
50-day moving average	$0.92
200-day moving average	$0.71
Wall St. target price	$1.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.78

Buy Neos Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Neos Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Neos Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Neos Therapeutics financials

Revenue TTM	$57 million
Gross profit TTM	$39.5 million
Return on assets TTM	-10.71%
Return on equity TTM	0%
Profit margin	-38.35%
Book value	$-0.03
Market capitalisation	$43 million

TTM: trailing 12 months

Shorting Neos Therapeutics shares

There are currently 1.2 million Neos Therapeutics shares held short by investors – that's known as Neos Therapeutics's "short interest". This figure is 9% down from 1.3 million last month.

There are a few different ways that this level of interest in shorting Neos Therapeutics shares can be evaluated.

Neos Therapeutics's "short interest ratio" (SIR)

Neos Therapeutics's "short interest ratio" (SIR) is the quantity of Neos Therapeutics shares currently shorted divided by the average quantity of Neos Therapeutics shares traded daily (recently around 5.9 million). Neos Therapeutics's SIR currently stands at 0.2. In other words for every 100,000 Neos Therapeutics shares traded daily on the market, roughly 200 shares are currently held short.

However Neos Therapeutics's short interest can also be evaluated against the total number of Neos Therapeutics shares, or, against the total number of tradable Neos Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Neos Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Neos Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0262% of the tradable shares (for every 100,000 tradable Neos Therapeutics shares, roughly 26 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Neos Therapeutics.

Find out more about how you can short Neos Therapeutics stock.

Neos Therapeutics share dividends

We're not expecting Neos Therapeutics to pay a dividend over the next 12 months.

Neos Therapeutics share price volatility

Over the last 12 months, Neos Therapeutics's shares have ranged in value from as little as $0.45 up to $1.37. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Neos Therapeutics's is 1.454. This would suggest that Neos Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Neos Therapeutics overview

Neos Therapeutics, Inc. , a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate to treat ADHD; Adzenys ER amphetamine for the treatment of ADHD; and generic Tussionex, a hydrocodone and chlorpheniramine polistirex XR oral suspension for cough and upper respiratory symptoms of a cold. It also offers NT0502, a clinical-stage product candidate that has completed Phase I pilot pharmacokinetic trial for the treatment of neurological conditions associated with excessive salivation and drooling to reduce chronic sialorrhea in patients. The company was incorporated in 2009 and is headquartered in Grand Prairie, Texas. .

Frequently asked questions

• What percentage of Neos Therapeutics is owned by insiders or institutions?

  Currently 1.503% of Neos Therapeutics shares are held by insiders and 33.384% by institutions.

• How many people work for Neos Therapeutics?

  Latest data suggests 213 work at Neos Therapeutics.

• When does the fiscal year end for Neos Therapeutics?

  Neos Therapeutics's fiscal year ends in December.

• Where is Neos Therapeutics based?

  Neos Therapeutics's address is: 2940 North Highway 360, Grand Prairie, TX, United States, 75050

• What is Neos Therapeutics's ISIN number?

  Neos Therapeutics's international securities identification number is: US64052L1061

• What is Neos Therapeutics's CUSIP number?

  Neos Therapeutics's Committee on Uniform Securities Identification Procedures number is: 64052L106